Evidence map›Paper›PMID 32979073›Full record

ArticleDiabetologia2021

Mortality in first- and second-generation immigrants to Sweden diagnosed with type 2 diabetes: a 10 year nationwide cohort study.

Louise Bennet, Ruzan Udumyan, Carl Johan Östgren, Olov Rolandsson, Stefan P O Jansson, Per Wändell

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Louise BennetDepartment of Clinical Sciences in Malmö, Lund University, Malmö, Sweden. louise.bennet@med.lu.se.ORCID 0000-0001-7101-1290
Ruzan UdumyanClinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.ORCID 0000-0001-9204-1165
Carl Johan ÖstgrenDepartment of Health, Medicine and Caring Sciences, General Practice, Linköping University, Linköping, Sweden.ORCID 0000-0003-1617-3179
Olov RolandssonDepartment of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0002-1341-6828
Stefan P O JanssonInstitution of Medical Sciences, University Health Care Research Center, Örebro University, Örebro, Sweden.ORCID 0000-0001-6864-4679
Per WändellDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0001-5169-2965
Karolinska Institutet · SELinköping University · SEMalmö University · SEÖrebro University · SEUmeå University · SEUppsala University · SE

Funding

Lund University Medical Faculty Foundation ALFStiftelsen för Strategisk Forskning Dnr IRC15-0067Vetenskapsrådet Dnr 349-2006-237
6 · The paper itself

Abstract

aims/hypothesisNon-Western immigrants to Europe are at high risk for type 2 diabetes. In this nationwide study including incident cases of type 2 diabetes, the aim was to compare all-cause mortality (ACM) and cause-specific mortality (CSM) rates in first- and second-generation immigrants with native Swedes.

methodsPeople living in Sweden diagnosed with new-onset pharmacologically treated type 2 diabetes between 2006 and 2012 were identified through the Swedish Prescribed Drug Register. They were followed until 31 December 2016 for ACM and until 31 December 2012 for CSM. Analyses were adjusted for age at diagnosis, sex, socioeconomic status, education, treatment and region. Associations were assessed using Cox regression analysis.

resultsIn total, 138,085 individuals were diagnosed with type 2 diabetes between 2006 and 2012 and fulfilled inclusion criteria. Of these, 102,163 (74.0%) were native Swedes, 28,819 (20.9%) were first-generation immigrants and 7103 (5.1%) were second-generation immigrants with either one or both parents born outside Sweden. First-generation immigrants had lower ACM rate (HR 0.80 [95% CI 0.76, 0.84]) compared with native Swedes. The mortality rates were particularly low in people born in non-Western regions (0.46 [0.42, 0.50]; the Middle East, 0.41 [0.36, 0.47]; Asia, 0.53 [0.43, 0.66]; Africa, 0.47 [0.38, 0.59]; and Latin America, 0.53 [0.42, 0.68]). ACM rates decreased with older age at migration and shorter stay in Sweden. Compared with native Swedes, first-generation immigrants with ≤ 24 years in Sweden (0.55 [0.51, 0.60]) displayed lower ACM rates than those spending >24 years in Sweden (0.92 [0.87, 0.97]). Second-generation immigrants did not have better survival rates than native Swedes but rather displayed higher ACM rates for people with both parents born abroad (1.28 [1.05, 1.56]). CONCLUSIONS/

interpretationIn people with type 2 diabetes, the lower mortality rate in first-generation non-Western immigrants compared with native Swedes was reduced over time and was equalised in second-generation immigrants. These findings suggest that acculturation to Western culture may impact ACM and CSM in immigrants with type 2 diabetes but further investigation is needed. Graphical abstract.

Indexed as

AdultAfricaAgedAsiaCohort StudiesDiabetes Mellitus, Type 2Educational StatusEmigrants and ImmigrantsEuropeFemaleHumansLatin AmericaMaleMiddle AgedMiddle EastMortalityAll-cause mortalityCause-specific mortalityFirst-generationImmigrantsIncidentNon-WesternSecond-generationSurvivalType 2 diabetes

Identifiers

PMID32979073
PMCPMC7716891
OpenAlexW3089185195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.